Avalo Therapeutics, Inc. Altman Z-Score
AVTX|Modified Z-Score (book value) based on FY2025 data
Avalo Therapeutics, Inc.'s Altman Z-Score of -3.59 places the company in the "distress zone" used by the Altman model (below 1.23) for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.59 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Distress Zone (< 1.23)
The score is below the 1.23 boundary used in the Altman model.
The Altman Z-Score uses 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2025 10-K filings.
5-Factor Decomposition
Working Capital / Total Assets
- Ratio
- 0.793
- Weight
- 0.717
- Contribution
- 0.569
Retained Earnings / Total Assets
- Ratio
- -3.851
- Weight
- 0.847
- Contribution
- -3.262
EBIT / Total Assets
- Ratio
- -0.626
- Weight
- 3.107
- Contribution
- -1.946
Book Equity / Total Liabilities
- Ratio
- 2.486
- Weight
- 0.420
- Contribution
- 1.044
Revenue / Total Assets
- Ratio
- 0.001
- Weight
- 0.998
- Contribution
- 0.001
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.793 | 0.717 | 0.569 |
| Retained Earnings / Total Assets | -3.851 | 0.847 | -3.262 |
| EBIT / Total Assets | -0.626 | 3.107 | -1.946 |
| Book Equity / Total Liabilities | 2.486 | 0.420 | 1.044 |
| Revenue / Total Assets | 0.001 | 0.998 | 0.001 |
| Total Z-Score | -3.59 | ||
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
Z-Score Zones
Safe Zone - score above the 2.9 boundary used in the Altman model.
Grey Zone - score between the 1.23 and 2.9 boundaries used in the Altman model.
Distress Zone - score below the 1.23 boundary used in the Altman model.